IPO for Amylyx Pharmaceuticals (AMLX) Opens 11% Higher

Today's IPO for Amylyx Pharmaceuticals (NASDAQ: AMLX) opened for trading at $21 after pricing 10,000,000 shares of common stock at $19 per share.

Goldman Sachs & Co. LLC, SVB Leerink, and Evercore ISI are acting as joint book-running managers for the offering. H.C. Wainwright & Co. is acting as lead manager for the offering.

Amylyx Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company working on developing a novel therapeutic for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases.

You May Also Be Interested In

• ADARx Pharmaceuticals files for proposed IPO
• H.C. Wainwright Starts Ascendis Pharma (ASND) at Buy
• DeFi Development Corp. plans $20M preferred stock offering